AGENUS INC — Form 8-K
Filed July 13, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 28/100
What the filing says
Agenus Inc. issued three types of warrants to investors dated July 2026: pre-funded warrants exercisable at $0.01; Series A warrants exercisable at $4.02 (expiring upon 60-patient dosing disclosure or 5 years); and Series B warrants exercisable at $5.03 (expiring upon 50-patient pathologic response data or Series A full exercise). Share counts and investor identities not disclosed in filing; pricing per share/warrant specified ($3.69 for shares with warrants; $3.68 for pre-funded). Warrant exercise prices are fixed; Series B has early termination tied to clinical trial progress on botensilimab/balstilimab colon cancer combination.
Why this rating
Warrant issuance is standard capital-raise mechanism for small-cap biotech. At ~$135M market cap, dilution effect depends on undisclosed share count. Milestone triggers add execution risk but are ordinary for clinical-stage companies. Routine financing event.
See more from July 13, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.